# The MHRA peptide-clinic investigation Canonical: https://europeanpeptideshop.com/blog/peptide-clinics-uk-mhra/ Explore the catalogue and research library. Ordering and shipping have not opened yet. Research news · 8 November 2026 · 2 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/) ### On this page UK peptide clinics have been under MHRA review since April 2026, after The Guardian reported that some were promoting unregulated, experimental peptides. The sources for this page report no outcome yet. ## Why is the MHRA investigating peptide clinics? Pharmacy Business says the MHRA "is investigating whether clinics are breaking the law" through claims about experimental peptide therapies. Aesthetics Journal named peptides including BPC-157 and Cortexin. An MHRA spokesperson said: "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation under the Human Medicines Regulations 2012." After The Guardian approached one clinic, "the claims were removed from the site". ## What has BCAM said about peptide clinics? The British College of Aesthetic Medicine issued a public warning in May 2026. Aesthetics Journal reports it said UK rules "prohibit the advertising of unlicensed medicines and prescription-only medicines to the public". ## Which law applies? The guide to the [Human Medicines Regulations 2012](https://europeanpeptideshop.com/blog/human-medicines-regulations-2012-peptides/) sets out the test. On the MHRA's reading, peptide clinics making medicinal claims fall inside it. For one compound, see [is BPC-157 legal in the UK](https://europeanpeptideshop.com/blog/is-bpc-157-legal-in-the-uk/). ## Scope for European readers This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the [research-use statement](https://europeanpeptideshop.com/research-use/) for the storefront's scope. ## Laboratory research only Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here. ## References - [Pharmacy Business, 7 April 2026](https://www.pharmacy.biz/mhra-peptide-injections-investigation-uk/) - [Aesthetics Journal, 15 April 2026](https://aestheticsjournal.com/news/mhra-investigates-clinics-following-peptide-claims/) - [Aesthetics Journal, 18 May 2026](https://aestheticsjournal.com/news/bcam-issues-warning-towards-peptide-injectables/) ## More articles Research news · 2 min read ## [MHRA's Birmingham fake-pen seizure](https://europeanpeptideshop.com/blog/mhra-birmingham-raid-fake-pens/) The MHRA Birmingham raid on 14 October 2026 seized over 12,000 fake retatrutide and tirzepatide pens worth about £2 million. What was found. 8 November 2026 Research news · 2 min read ## [Australia's Synedica peptide warning](https://europeanpeptideshop.com/blog/synedica-tga-warning-australia-tb-500/) Australian testing found Synedica peptide products contained no TB-500 and less retatrutide than labelled. The TGA has told Australians to discard them. 8 November 2026 Research news · 3 min read ## [Avexitide and the LUCIDITY trial](https://europeanpeptideshop.com/blog/avexitide-glp-1-antagonist-lucidity/) Why does avexitide block GLP-1? Explore post-bariatric hypoglycemia, LUCIDITY results and Amylyx’s November 2026 FDA-filing and conference plans. 8 November 2026